A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer
NCT06631989
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
100
Enrollment
INDUSTRY
Sponsor class
Conditions
EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
Interventions
DRUG:
WSD0922-FU
Sponsor
Wayshine Biopharm, Inc.